Nurix Therapeutics, Inc.
NRIX
$12.46
$0.201.59%
NASDAQ
| 08/31/2025 | 05/31/2025 | 02/28/2025 | 11/30/2024 | 08/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -76.53% | 2.43% | -35.73% | -39.55% | -32.38% |
| Total Depreciation and Amortization | 20.60% | 24.59% | 6.17% | 27.41% | 22.52% |
| Total Amortization of Deferred Charges | -- | -- | -- | -7.14% | -- |
| Total Other Non-Cash Items | 42.01% | 14.93% | -12.34% | -16.84% | -26.41% |
| Change in Net Operating Assets | 709.44% | -447.14% | -37.36% | -99.24% | 81.73% |
| Cash from Operations | -36.06% | -59.08% | -45.62% | -282.66% | -2.54% |
| Capital Expenditure | -15.51% | -38.10% | -20.84% | 18.57% | 4.55% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 380.04% | 157.44% | -24.43% | -1,076.72% | -175.26% |
| Cash from Investing | 336.54% | 154.55% | -28.10% | -879.73% | -193.69% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -97.48% | -100.00% | -9.30% | 2,864,485.71% | 2,586.03% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -97.48% | -100.00% | -9.30% | 2,864,485.71% | 2,586.03% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 67.57% | -87.54% | -607.96% | -11.12% | -6.56% |